Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Lonapegsomatropin (Skytrofa) vs Sermorelin
An educational, source-based comparison of Lonapegsomatropin (Skytrofa) and Sermorelin — how each peptide works, what it's researched for, and what to know before going deeper.
Prodrug of somatropin with a transient PEG linker that releases unmodified GH over ~1 week, providing once-weekly dosing for pediatric GH deficiency.
- Pediatric growth hormone deficiency
- • FDA-approved.
- • Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
A synthetic 29-amino-acid analog representing the active fragment of endogenous GHRH. Stimulates the pituitary to release GH in a physiologic, pulsatile pattern. Previously FDA-approved (Geref) for pediatric GH deficiency diagnosis before discontinuation for commercial reasons.
- Adult GH deficiency
- Pediatric short stature (historical)
- Sleep quality and body composition in aging
- • No longer commercially available as an FDA-approved drug; available via compounding.
- • Requires physician oversight.
- • Banned in competitive sport.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Lonapegsomatropin (Skytrofa) | heiGHt trial | JCEM | 2021 | Non-inferior annualized height velocity vs daily somatropin. |
| Sermorelin | Sermorelin in adult growth hormone deficiency | Endocrine Practice | 2010 | Reviewed efficacy on body composition, energy, and sleep markers. |
Side-effect & safety grid
- FDA-approved.
- Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
- No longer commercially available as an FDA-approved drug; available via compounding.
- Requires physician oversight.
- Banned in competitive sport.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Lonapegsomatropin (Skytrofa) vs Sermorelin — Key differences
- Class: Lonapegsomatropin (Skytrofa) is classified as GH Analog · Endocrine, while Sermorelin is Growth Hormone Axis.
- Primary research focus: Lonapegsomatropin (Skytrofa) — pediatric growth hormone deficiency; Sermorelin — adult gh deficiency.
- Tag: FDA-Approved · Endocrine vs Growth hormone.